急性髓系白血病异基因移植后的免疫治疗策略
异基因造血干细胞移植(allo-SCT)通过T细胞和NK细胞介导的移植物抗白血病(GVL)效应治疗急性髓系白血病(AML),但移植后复发常见且预后差。本文综述了移植后AML免疫治疗的进展,包括供者淋巴细胞输注(DLI)、免疫检查点抑制剂及其他单克隆抗体(含抗体药物偶联物和配体受体拮抗剂),并讨论了去甲基化药物、组蛋白去乙酰化酶抑制剂和FLT3抑制剂索拉非尼等具有免疫机制的疗法。
要点
- allo-SCT是AML最成功的免疫治疗,GVL效应由T细胞和NK细胞驱动。
- 移植后复发常见且预后差,免疫策略旨在增强GVL效应以预防复发或再诱导缓解。
- 免疫检查点抑制剂等可增强GVL但可能加重GVHD,限制其广泛应用。
核心结论
- allo-SCT后免疫治疗是增强GVL效应、预防复发和改善预后的有前景策略,但GVHD加重限制部分疗法应用。
研究设计与样本
- 本文为综述,检索并汇总了移植后AML免疫治疗三个领域的研究进展。
主要发现
- 免疫检查点抑制剂和其他新型免疫靶向药物在小型临床试验中可增强GVL效应并使复发患者缓解。
- GVHD加重限制了免疫检查点抑制剂等疗法的更广泛应用。
临床怎么用
- 移植后可考虑DLI、免疫检查点抑制剂或其他单克隆抗体等免疫策略以增强GVL效应。
- 使用免疫检查点抑制剂等需警惕GVHD加重风险。
局限性
- 免疫检查点抑制剂等疗法的证据来自小型临床试验。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
Allogeneic stem cell transplantation (allo-SCT) is the most successful and widely used immunotherapy for the treatment of acute myeloid leukemia (AML), as a result of its anti-leukemic properties driven by T cells and natural killer (NK) cells, leading to a graft-vs-leukemia (GVL) effect. Despite its essential role in AML treatment, relapse after allo-SCT is common and associated with a poor prognosis. There is longstanding interest in developing immunologic strategies to augment the GVL effect post-transplant to prevent relapse and improve outcomes. In addition to prophylactic maintenance strategies, the GVL effect can also be used in relapsed patients to reinduce remission. While immune checkpoint inhibitors and other novel immune-targeted agents have been successfully used in the post-transplant setting to augment the GVL effect and induce remission in small clinical trials of relapsed patients, exacerbations of graft-vs-host disease (GVHD) have limited their broader use. Here we review advances in three areas of immunotherapy that have been studied in post-transplant AML: donor lymphocyte infusion (DLI), immune checkpoint inhibitors, and other monoclonal antibodies (mAbs), including antibody-drug conjugates (ADCs) and ligand receptor antagonists. We also discuss additional therapies with proposed immunologic mechanisms, such as hypomethylating agents, histone deacetylase inhibitors, and the FLT3 inhibitor sorafenib.
引用
- Sterling C, Webster J. Harnessing the immune system after allogeneic stem cell transplant in acute myeloid leukemia. Am J Hematol. 2020. PMID: 32022292. doi:10.1002/ajh.25750
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。